UH student earns prestigious award for cancer vaccine research

up-and-comer

Cole Woody has earned the Barry Goldwater Scholarship for his research on personalized cancer-fighting vaccines. Photo courtesy UH.

Cole Woody, a biology major in the College of Natural Sciences and Mathematics at the University of Houston, has been awarded a Barry Goldwater Scholarship, becoming the first sophomore in UH history to earn the prestigious prize for research in natural sciences, mathematics and engineering.

Woody was recognized for his research on developing potential cancer vaccines through chimeric RNAs. The work specifically investigates how a vaccine can more aggressively target cancers.

Woody developed the MHCole Pipeline, a bioinformatic tool that predicts peptide-HLA binding affinities with nearly 100 percent improvement in data processing efficiency. The MHCole Pipeline aims to find cancer-specific targets and develop personalized vaccines. Woody is also a junior research associate at the UH Sequencing Core and works in Dr. Steven Hsesheng Lin’s lab at MD Anderson Cancer Center.

“Cole’s work ethic and dedication are unmatched,” Preethi Gunaratne, director of the UH Sequencing Core and professor of Biology & Biochemistry at NSM, said in a news release. “He consistently worked 60 to 70 hours a week, committing himself to learning new techniques and coding the MHCole pipeline.”

Woody plans to earn his MD-PhD and has been accepted into the Harvard/MIT MD-PhD Early Access to Research Training (HEART) program. According to UH, recipients of the Goldwater Scholarship often go on to win various nationally prestigious awards.

"Cole’s ability to independently design and implement such a transformative tool at such an early stage in his career demonstrates his exceptional technical acumen and creative problem-solving skills, which should go a long way towards a promising career in immuno-oncology,” Gunaratne added in the release.

From Your Site Articles
The new collaborative hub will foster research into cell therapies, artificial intelligence, nanotechnologies, and more. Photo via tmc.edu

Houston health care leaders announce new hub for cancer-fighting bioengineering

team work

Two Houston organizations recently announced a new hub that will focus on developing cell therapies, nanotechnologies, cancer vaccines, artificial intelligence, and molecular imaging.

Rice University and The University of Texas MD Anderson Cancer Center have teamed up to “drive industry growth and advance life-saving technologies” through the newly established Cancer Bioengineering Collaborative, according to a news release announcing the initiative.

The collaboration between the two institutions includes fundamental and translational cancer research, developing new technologies for cancer detection and therapy, and securing external funding in support of further research and training.

Leading the hub will be Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem.

“There is tremendous potential in bringing together experts in engineering and cancer as part of this focused, collaborative framework that is truly unique, not only owing to the complementary nature of the respective strengths but also because this is the first formal joint research initiative of its kind between the two institutions,” says Bao, department chair and Foyt Family Professor of Bioengineering, professor of chemistry, materials science and nanoengineering and mechanical engineering, in the release.

The joint effort will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering, and also a seed grant program to fund research projects in the early stages of development.

“From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, says in the release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.”

Dr. Jeff Molldrem (left) and Gang Bao will lead the new collaborative hub. Photo via MD Anderson

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice University launches new venture fund for university-affiliated startups

startup support

Rice University has launched its new One Giant Leap Ventures Fund I, which will invest in the university’s spinouts and alumni-founded startups.

The early-stage institutional venture fund will function with a hybrid structure that allows for participation from traditional equity investors and philanthropic investors. According to the university, the fund will invest up to $500,000 per Rice-affiliated company.

To be considered eligible for funds, companies must use intellectual property licensed by the university or be led or founded by alumni.

One Giant Leap will draw on support and mentorship from Rice’s pool of 60,000 alumni and aims to create educational opportunities within the investment phases, work with graduate and undergraduate venture students, explore the scaling and commercialization of their ideas, and help investigate all the facets of venture capital.

“Rice alumni bring an extraordinary depth of experience as entrepreneurs, investors and industry leaders, and One Giant Leap creates new ways to put that expertise to work for the next generation of Rice innovators,” Stephen Bayer, vice president for development and alumni relations, said in a news release. “It strengthens the connection between our alumni and the university while giving them meaningful opportunities to mentor, advise and support Rice-affiliated companies as they grow.”

The fund held its first close in August and made its first investment into Rice brain health spinout Motif Neurotech. Led by Rice faculty member Jacob Robinson, Motif is working to commercialize a minimally invasive neurostimulator that targets treatment-resistant depression. In May, the FDA approved the company to move forward with its first clinical trial.

“Research produces breakthrough technologies and our academic environment forms outstanding entrepreneurs,” said Adrian Trömel, the fund’s managing director, a Rice alumnus and a startup founder who also serves as Rice’s interim chief innovation officer.

One Giant Leap joins the already long list of Rice-led programs that foster innovation, including the Liu Idea Labs for Innovation and Entrepreneurship’s Innovation Fellows and Summer Venture Studio, the Rice Alliance’s Business Plan Competition, the Ion District, Woodside Rice Decarbonization Accelerator, Rice Nexus, the Biotech Launchpad and RBL Ventures and its upcoming 200,000 square-foot research lab the Arc.

“With One Giant Leap, I am excited that we are creating a unique structure that brings together traditional investment and philanthropic participation to invest in and help catalyze our startups, engage the deep expertise within the Rice ecosystem and transform those strengths into real-world impact,” Trömel added in the release.

New statewide plan aims to eliminate cervical cancer in Texas by 2032

fighting cancer

MD Anderson, on behalf of a coalition of health systems, has announced a new plan to eliminate cervical cancer in Texas.

The five-year Texas Lone Star Cervical Cancer Elimination Plan was launched during the Cancer Prevention and Research Institute of Texas (CPRIT) 2026 Innovations Conference in Galveston this month.

The plan focuses on three major pillars with goals to be achieved by 2032:

  • HPV vaccination: Increase the percentage of Texas boys and girls up to date on human papillomavirus (HPV) vaccination by age 15 from 50.5 percent to 80 percent
  • Cervical cancer screening: Raise the share of Texas women up to date on cervical cancer screening from 64 percent to 80 percent
  • Timely follow-up, diagnosis and treatment: Ensure 80 percent of women receive diagnostic follow-up and treatment when needed through community outreach, patient navigation, provider training and survivorship support

Overall, the coalition wants to see fewer than four new cases of cervical cancer annually per 100,000 Texas women by 2032, according to a news release from MD Anderson. Currently, Texas has an incidence rate of 9.5 women per 100,000 diagnosed with cervical cancer, compared with 7.5 women per 100,000 nationally.

“Texas has the tools to prevent nearly every case of cervical cancer, but tools can save lives only when people can utilize them,” Dr. Ernest Hawk, vice president and division head of Cancer Prevention and Population Sciences at MD Anderson, said in the release. “The Lone Star Cervical Cancer Elimination Plan gives us a shared roadmap to vaccinate more of our children, screen more of our women and make sure every abnormal result leads to care. With innovations like HPV self-collection and the commitment of partners across the state, elimination is within reach.”

About 40 other hospitals, health care organizations and companies join MD Anderson in the coalition that launched the Lonestar Plan. Those based in Houston include Houston Methodist, Rice University, UTHealth Houston, Texas Children's Hospital, Houston Health Department and others.

The CPRIT also announced its Texans Conquer Cancer Awards and its CPRIT Champion awards during the Innovations Conference this week. Several are based in Houston, including:

  • Zhiqiang An, co-founder of CrossBridge Bio, Director of the Texas Therapeutics Institute, and Vice President of Drug Discovery at the University of Texas Health Science Center at Houston
  • Dr. Abbey Berenson, Director of the UTMB Center for Interdisciplinary Research in Women's Health Care
  • Dr. Michael Taylor, Chair of Pediatric Neuro-Oncology at Texas Children's Cancer and Hematology Center and Director of Texas Children's Pediatric Brain Tumor Research Program

To date, the CPRIT has awarded more than $4.2 billion in grants to fight cancer in the state. Over the summer, it awarded four $2 million grants to institutions in Houston and Bryan for the creation or expansion of “core” cancer research facilities.

Texas Medical Center Innovation recently announced that its $2 million grant would renew its Accelerator for Cancer Therapeutics for five years. Read more from TMCi about the renewal here.

Announcing the 2026 Houston Innovation Awards finalists

Inspirational Innovators

InnovationMap is proud to reveal the finalists for the 2026 Houston Innovation Awards.

The sixth annual Houston Innovation Awards program returns in an all-digital format this fall to honor the best of Houston's innovation ecosystem, including startups, entrepreneurs, mentors, and more.

Finalists were determined by our esteemed panel of judges, comprised of past award winners and InnovationMap editorial leadership.

The panel reviewed applications across 10 prestigious categories to determine our finalists. They will select the winner for each category, except for Startup of the Year, which will be chosen by the public via online voting launching later this month.

We will announce the honoree of our annual Trailblazer Award in the coming weeks, then stay tuned as we unveil all of this year's winners on InnovationMap.com in mid-November.

Get to know our finalists in more detail through editorial spotlights leading up to the winner announcement. Without further ado, here are the 2026 Houston Innovation Awards finalists:

Minority-founded Business

Honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation:

  • AI Made Fun
  • Deep Anchor Solutions
  • HEXAspec
  • Prana Surgical
  • Torres Orbital Mining Inc.

Female-founded Business

Honoring an innovative startup founded or co-founded by a woman:

  • Adair
  • ARIX Technologies
  • Bairitone Health
  • FlowCellutions
  • ParaDocs Health

Energy Transition Business

Honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy and beyond:

  • Capwell Services
  • FlowCellutions
  • Hertha Metals
  • Mars Materials
  • Solidec

Health Tech Business

Honoring an innovative startup within the health and medical technology sectors:

  • Bairitone Health
  • InformAI Inc.
  • Prana Surgical
  • Skybound MedTech

Deep Tech Business

Honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors:

  • Casimir
  • Focis AI
  • Machine Saver Inc.
  • Square Robot
  • Venus Aerospace

Startup of the Year (People's Choice)

Honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an online voting experience:

  • Fluxworks
  • IronLattice
  • Lumino
  • Progress Report
  • Rosarium Health
  • Thread
  • TokenRoster

Scaleup of the Year

Honoring an innovative later-stage startup that's recently reached a significant milestone in company growth:

  • Erock
  • Hertha Metals
  • Venus Aerospace

Incubator/Accelerator of the Year

Honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups:

  • Activate
  • Impact Hub Houston
  • MarMo Innovation

Mentor of the Year

Honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs:

  • Al Danto, Rice University
  • Eric Rubenstein, New Climate Ventures
  • Jeremy Pitts, Activate
  • Joe Alapat, Liongard
  • Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship
  • Rachel Bickham, Bickham Services Unlimited LLC

Trailblazer Recipient

  • To be announced
View All Listings